KRRO

Korro Bio, Inc. (KRRO) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing genetic medicines based on RNA editing (the OPERA platform). The company is an emerging growth company and a smaller reporting company. As of November 7, 2024, there were 9,368,262 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by $4.1 million (22%) for the three months ended September 30, 2024, compared to the same period in 2023. This was driven by higher Research and Development (R&D) costs ($16.0M vs $14.0M) and General and Administrative (G&A) costs ($7.3M vs $5.1M).
• R&D Drivers: The increase in R&D expenses was primarily due to a $1.3 million increase in discovery, preclinical, and contract manufacturing costs in preparation for the first-in-human trial of KRRO-110, alongside increased personnel costs.
• G&A Drivers: The increase in G&A expenses was driven by higher employee-related expenses due to headcount growth, increased professional service fees, and higher IT and insurance costs.
• Other Income: Other income, net, increased significantly to $2.3 million for Q3 2024 from $0.7 million in Q3 2023, primarily due to higher interest income on cash and marketable securities.
• Capital Structure: In April 2024, the company completed a PIPE financing raising approximately $70.0 million. In September 2024, the company entered into a collaboration with Novo Nordisk.

Guidance, Outlook, and Management Commentary

• Novo Nordisk Collaboration: On September 13, 2024, Korro Bio entered into a research collaboration and license agreement with Novo Nordisk. The deal includes an upfront payment of $10.0 million (received in October 2024) and potential total payments of up to $530.0 million plus tiered royalties for two programs in the cardiometabolic field.
• Clinical Progress: The company's most advanced program, KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD), had a regulatory filing submitted to the Australian Bellberry Human Research Ethics Committee in November 2024. Dosing of the first participant in the Phase 1/2 trial is anticipated in Q1 2025, with an interim data readout expected in H2 2025.
• Liquidity and Runway: Management expects that existing cash, cash equivalents, and marketable securities of $169.1 million will be sufficient to fund operations and capital expenditure requirements into the second half of 2026.
• Profitability: The company has incurred significant losses since inception and expects to continue to incur losses for the foreseeable future. It has never generated revenue from product sales.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the management's projection that current liquidity ($169.1M) will sustain operations through H2 2026, given the burn rate of approximately $52.6M over the last nine months.
• Novo Nordisk Milestones: Monitor the timing and conditions for the $10M upfront payment (received Oct 2024) and the potential $530M in future milestones to assess revenue recognition timelines.
• KRRO-110 Trial Initiation: Confirm the acceptance of the regulatory filing by Australian authorities and the actual start date of the Phase 1/2 clinical trial in Q1 2025.
• Expense Trajectory: Track the trend in R&D and G&A expenses to ensure they align with the planned clinical trial initiation and do not accelerate the need for additional capital raising.
• Legal Proceedings: Review the status of the dismissed class action lawsuit regarding Frequency Therapeutics (predecessor) to ensure no new motions or appeals are pending that could result in liability.